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Multi-parametric MRI and PET imaging for dose painting in head-
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The benefit of dose painting in the head-and-neck (HN) area is 
currently being investigated in several clinical trials. In these trials, 
dose painting is based on a single imaging modality, 18F-
fluorodeoxyglucose positron emission tomography (FDG-PET). FDG-PET 
identifies aggressive or radiation resistant subvolumes, as it 
represents the cumulative effect of multiple adverse tumor 
characteristics, such as high cell metabolism, proliferation, expression 
of key oncogenes, and hypoxia. Other PET tracers and (functional) 
magnetic resonance imaging (MRI) techniques that visualize the 
complex and heterogeneous biology of the tumor have been 
published.  
The key question is which (combination) of these imaging modalities 
are relevant to guide dose painting in HN cancer and how will we gain 
this knowledge? 
First of all, we need to investigate whether different imaging 
techniques identify the same or different target volumes for dose 
escalation. Secondly, for the imaging techniques reflecting different 
targets, the relation between imaging parameter and required dose 
needs to be defined. To avoid a large amount of trials, multiple 
imaging techniques of interest can be combined in clinical trials. 
Together with extensive follow-up imaging, this will open up the 
possibility to relate tumor areas requiring a higher dose to the 
functional imaging parameters. 
As an example, we investigated in 18 patients with a HN tumor 
whether target volumes defined using FDG-PET or DWI are the same or 
different. Furthermore, the dose coverage of DWI targets in FDG-PET-
based dose painting plans was analyzed. To this end, the FDG-PET 
target for dose painting was determined as the area with a 
standardized uptake value (SUV) above 50% of the maximum SUV in 
the GTV, as is typically done in ongoing trials. For DWI, the relation 
between the apparent diffusion coefficient (ADC) and the required 
dose is not clear yet. While a low ADC value is indicative of tumor 
presence, others reported that a higher ADC within the tumor is 
associated with worse outcome. Therefore, we determined different 
ADC target volumes, with values above and below the mean ADC value 
within the GTV. 
The correspondence between these imaging techniques in the GTV, 
determined on a voxel-level using Spearman’s correlation coefficient, 
varied between positive and negative correlations (ρ ranged from -0.6 
to 0.4). The dose coverage of all ADC-targets was significantly 
reduced compared to the coverage of the FDG-PET-target (Dmean(SUV) 
= 81 Gy, Dmean(ADC) = 75-77Gy; D98%(SUV) = 77 Gy; D98%(ADC) = 70 Gy). 
This could mostly be explained by the partial overlap between the 
volumes. 
In conclusion, different imaging modalities can contain different 
information, resulting in different targets. Further knowledge about 
failure patterns and relations between the required dose and imaging 
parameters need to be obtained by adding such imaging techniques to 
dose painting trials.  
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Choline is an essential part of the cell wall, and substantial amounts 
are required for cellular proliferation. The biodistribution of choline 
can be visualized in vivo by introducing a radioactive label suitable for 
positron emission detection (PET), either 11-Carbon or 18-Fluor. The 
accumulation of radiolabeled choline on PET/CT provides a visual 
representation of cell proliferation. This technique can be applied to 
detect tumour types that proliferate but tend to be FDG-negative, 
such as prostate cancer. Choline PET/CT has some drawbacks that 
need to be considered. It is relatively expensive, it comes with a 
radiation burden, and it can only detect macroscopic tumor lesions. 
Therefore, it is important to properly select patients with a high 
chance of clinical impact. 
Since normal prostate gland tissue tends to accumulate choline for 
physiological purposes, discrimination of a primary tumour within a 
functioning prostate is difficult and may be unreliable. After 
treatment of prostate cancer, either with prostatectomy, external 
beam radiotherapy or brachytherapy, there no longer is functional 
prostate gland tissue in situ and detection of a local recurrence is 
reliable. Therefore, the main application of Choline PET/CT for 
prostate cancer is restaging at the time of PSA relapse. In addition, 
regional lymph node metastases and distant metastases can be 
detected with good accuracy. To further maximise diagnostic yield, 
criteria can be used to select patients with a good chance of visible 
macroscopic tumor, including PSA thresholds and Gleason score. 
The clinical impact of Choline PET/CT for restaging of recurrent 
prostate cancer is twofold. First, in cases where salvage 
prostatectomy or salvage radiotherapy is considered, the detection of 
regional or distant metastatic disease may switch treatment to 
systemic options, and avoid unnecessary aggressive invasive 
procedures with high cost and toxicity. Second, some patients may 
present with oligometastatic disease, where radiotherapy may find a 
new role with SBRT, aiming for high local control and postponing 
hormone treatment with potentially several years. In conclusion, in 
properly selected patients with recurrent prostate cancer, Choline 
PET/CT may guide treatment decisions to improve quality of life. 
Further research may focus on the application of Choline PET for 
radiotherapy planning and dose painting. Once the location of tumor 
tissue is known, e.g. as determined on MR, PET, US or biopsy, the 
local choline influx may be related to the radiation dose required for 
tumor sterilization. However, to allow such an approach, more 
knowledge is needed on the relations of functional imaging 
parameters from various imaging modalities with radiobiological 
tumor characteristics. 
 
 DEBATE: ELECTRONS, THE LOST PARTICLE: ARE 
THEY STILL IN CHARGE?  
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Electrons, the lost particle: Are they still in charge? - For the 
motion! 
M. Karlsson1 
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Electrons should be used in an integrated planning and delivery 
procedures together with photons!   
Electrons do not spill dose behind the target which significantly 
reduces the extra-target dose. Electrons can also deliver superficial 
dose without adding bolus. However, the electron penumbra is not so 
sharp at depth; this is where the modulated photons can help. 
So, what needs to be done?  
The planning systems must be developed to optimize both electrons 
and photons together. The fully computer controlled therapy 
accelerators must be able to deliver both electrons and photons with 
the same MLC. The accelerators must also allow for fast energy 
switching within the same sequence.  
The feasibility of this mixed-beam concept has been shown by several 
authors in the scientific literature. 
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Electron beam radiotherapy has more use in selling high energy 
radiotherapy machines than it has to treat patients. Before intensity-
modulated radiotherapy (IMRT) electron beams were used in about 5% 
of radiotherapy treatments. With the advent IMRT, the role of 
electron beam radiotherapy has greatly diminished for a number of 
reasons. Most importantly, many lower head and neck treatments that 
used both conformal photon beams and electron beams now are only 
using only IMRT photon beams because the plans are both better and 
easier to do. Other examples of treatments that can be done with 
photon IMRT alone are breast radiotherapy with internal mammary 
chain node boost or skin boost. When electron treatments are 
performed the tumor homogeneity is poor and the dose uncertainty is 
very high. Treatments that were once electron-only can now often be 
done better with IMRT. Examples include total scalp treatment and 
even small complex electron fields. Photon beam treatment planning 
accuracy has improved so much that it is not even always necessary to 
apply a bolus to the skin but rather the buildup is obtained by 
tangential fields. Conversely electron beam dose computation has 
more uncertainty than IMRT dosimetry. Likely less than 1% of patients, 
who are treated at centers which are fully IMRT capable, have 
electron beams applied to them and many of these treatments are for 
palliative or non-life threatening treatments like refractory planters 
warts. The cost of multi-energy and multi-modality radiotherapy 
equipment is much more than low energy units even with a full IMRT 
capability. A principle of industrial engineering that seems to be lost 
in radiotherapy is that all equipment in an industry does not have to 
be designed to be applied universally. There should likely be one 
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electron capable machine in the largest cancer centers but to have 
most machines capable of treating electrons is wasteful and in the 
future unsustainable.  
 
 SYMPOSIUM: ADVANCE PRACTICE FOR RTT 
RESEARCH: THE GEOMETRIC UNCERTAINTIES CASE  
  
SP-0112   
The national radiotherapy strategy in England: supporting 
implementation of national recommendations  
C. Beardmore1 
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Each country in the UK England, Scotland, Wales and Northern Ireland 
has its own health policy related to the development of services 
within the National Health Service (NHS).  This presentation focuses 
on work undertaken within England in relation to NHS Radiotherapy 
service provision.  
In England there are 50 NHS Radiotherapy providers, with 
radiotherapy services provided on 58 clinical sites.   The presentation 
will describe how a nationwide approach is helping support 
implementation of equitable high standards for patients across 
England.  
To enable this approach government established a National 
Radiotherapy Advisory Group to advise government ministers.  This 
group comprised professional representatives from each discipline, 
health care commissioners, patients and lay representatives and 
policy advisors from the Department of Health. The group made 
recommendations in the Report to Ministers in 2007 “Developing a 
world class Radiotherapy service for England” 1.   
The report made wide ranging recommendations about all aspects of 
service delivery including importantly standards of care related to 
technical service delivery.  A National Radiotherapy Implementation 
Group (NRIG) was established to oversee and support implementation 
of the recommendations2.  In 2011 the government set an ambitious 
goal to improve cancer patient’s outcomes, a national strategy 
Improving Outcomes: A strategy for cancer was published3.  This 
policy document built upon the radiotherapy NRAG recommendations 
and recommended an increase in capacity,  and implementation of 
the most up to date treatment technologies across England stating “ 
to improve outcomes from radiotherapy, there must be equitable 
access to high quality, safe, timely, protocol driven quality controlled 
services focused around patients’ needs”.   
This presentation focussing upon this work from 2007 to 2013, will 
describe the development of programmes and workstreams to support 
the implementation of the technical recommendations made within 
NRAG report.     
NB Specific details relating to the NRIG IGRT support programme will 
be provided by June Dean and Mark Elsworthy, National IGRT leads, 
Society of Radiographers and National Cancer Action Team in a paper 
within this session at ESTRO.  
1. NRAG (2007)  Radiotherapy: Developing a world class service for 
England , Report to Ministers from National Radiotherapy Advisory 
Group 26 February 2007. Accessed on line 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Pub
licationsPolicyAndGuidance/DH_074575  
2. Department of Health (2012) Radiotherapy Services in England 
2012.  Department of Health. London. Accessed on line 
https://www.wp.dh.gov.uk/publications/files/2012/11/Radiotherapy-
Services-in-England-2012.pdf 
 
3. Department of Health (2011) Improving Outcomes: A Strategy for 
Cancer. Department of Health. London. Accessed on line 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Pub
licationsPolicyAndGuidance/DH_123371  
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The employment of advanced image guidance techniques in clinical 
radiotherapy practice has ensured that geometrical uncertainties 
during treatment have been reduced. Hence, new techniques such as 
IMRT, and VMAT performed in a stereotactic setting can be applied 
safely with smaller margins.  
In our institute, the development of new radiotherapy (RT) techniques 
generally starts with retrospective studies on existing patient data. 
For example, to determine the required safety margin for a certain 
protocol, historic data will be analysed to determine organ motion, 
setup errors, and delineation variability in relation to the new 
protocol. To facilitate this, all patient imaging data are saved in 
databases and archived after patients have finished their treatment. 
Radiotherapy technicians (RTTs) often play an important role in 
collecting and managing these patient data, not only during treatment 
but also in its retrospective analysis.  
The collected data are analyzed by a research RTT, in close 
cooperation with a physicist and/or physician. This is followed by a 
proposal for introduction into the clinic, accompanied with a clinical 
implementation protocol. An IGRT implementation group, consisting 
of physicists, radiation oncologists and RTTs will guide and define the 
complete process from research to clinical implementation. After 
clinical implementation the newly developed technique is supervised 
by dedicated imaging RTTs until the technique is sufficiently 
imbedded in daily clinical practice. Once all other RTTs are 
sufficiently trained, the technique is fully implemented. During the 
whole process the technique will be evaluated and improvements can 
be made.   
To illustrate this procedure: We investigated the use of an optical 
imaging system (AlignRT) for monitoring the breath hold state of the 
patients during deep inspiration breath-hold RT. Data of 20 patients 
were collected and retrospectively analyzed to investigate geometric 
uncertainties such as inter-fraction, intra-fraction- and intra-beam 
variability. The results were used to evaluate the current kV guided 
breath-hold protocol and a number of adaptations were made as a 
result. 
 
SP-0114   
The role of the UK IGRT lead RTTs and outcome of the UK 
implementation program 
J. Dean1, M. Elsworthy2 
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A report to ministers in 2007 by the national radiotherapy advisory 
group proposed a vision for future radiotherapy; that all new linear 
accelerators would be capable of 4D Adaptive Radiotherapy and this 
would become the standard of care in the future. 
A new document was required to support the wider adoption and 
application of image guided radiotherapy (IGRT) to enable the future 
implementation of 4D adaptive radiotherapy throughout England. 
The national implementation strategy proposed that IGRT support 
leads would be sent to each centre in England that requests support. 
The leads would be members of a multi-professional team consisting 
of oncologists, physicists and radiographers. 
Radiographers are providing on- site support in developing protocols, 
work instructions and training and reviewing current practice. Physics 
support is provided by 3 English centres and is an outreach service via 
e-mail or telephone. Oncologist support will be directed appropriately 
by the co-chair of the new IGRT guidelines group. 
The exit strategy of the IGRT Leads will be to generate a report on the 
current level of IGRT accessibility in England and a second for 
manufacturers regarding the functionality of the equipment with user 
feedback. 
Data will be presented regarding common themes of support provided. 
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Combining research and clinical work - a radiation technologist's 
experience of multi-tasking 
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The professional role of radiation therapy technologists (RTTs) has 
changed tremendously over the last two decades. This presentation 
will give a brief overview of these changes in the Netherlands, and 
discuss the training requirements to become an Advanced RTT 
Practitioner (AP) as well as some of the roles open to the AP in this 
country. A personal perspective is presented on studying for a 
Master’s degree that focused on image guidance for stereotactic spine 
radiotherapy alongside clinical work, and subsequently on combining 
research and clinical work in an academic medical centre.  
In order to become an AP, an RTT in the Netherlands is expected to 
undertake a Master’s degree in a relevant aspect of radiotherapy in 
addition to possessing the necessary clinical experience and personal 
attributes. Working with senior management to define their role, 
advanced RTT practitioners are increasingly active in professional 
training and education, research and development, and improving and 
delivering high-quality patient cancer care. They may take on 
extended clinical responsibilities in areas like image guidance and 
advanced treatment planning for example, perform some of the tasks 
